[Ergobat and Daivonex in complex therapy of psoriasis].
According to data received in recent years, abnormality of phosphorous-calcium metabolism is revealed in patients with psoriasis. The combination of hypocalcemia and hypophosphatemia is considered as an indication of the relative deficiency of vitamin D. The aim of this study was the assessment of therapeutic efficacy of domestic drugs Ergobat and Daivonex in the treatment of patients with psoriasis. Under observation were 25 patients with psoriasis. Patients with lesion area less than 25% of body surface have been selected for study. Progressive stage of Dermatosis has been revealed in all patients. They were divided into 2 groups. Both groups were comparable by sex, age, onset of the disease, its duration and clinical forms and the value of PASI. The application of Daivonex ointment was included in the therapy of both groups of patients. After 28 days of therapy the reliable improvement in the skin processes was achieved in the group of patients, in which along with local application of Daivonex ointment the treatment with Ergobat was used. Active regressing of psoriatic rash and jump into the stationary phase began at 2,1+/-0,1 days earlier than in the group of patients taking just Ergobat. The contents of total calcium and inorganic phosphorus in the blood serum by the end of treatment reached the normal level in the patients taking Ergobat, such a trend in the control group we have not observed. Thus, our clinical observations allow recommending the prescription of a consistent scheme of Daivonex and Ergobat treatment in order to stabilize the psoriatic process.
N V
NV
Tsiskarishvili
Ts I
TsI
Tsiskarishvili
D000293:Adolescent; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D003879:Dermatologic Agents; C055085:calcipotriene; D002117:Calcitriol